Novel pigment treatment re-launches as Cyspera®
Cysteamine® is set to re-launch in the UK on 6 September 2019 as ‘Cyspera®’.
The new brand strategy comes after in-depth research by scientists, as well as market analysis and talking with clients. Results of this investigation showed that ‘Cyspera®’ would better resonate with clients and consumers to truly represent the functional and emotional benefits of the treatment of pigmentation with Cysteamine®.
The name Cyspera® was created from a combination of the two words ‘cysteamine’ and ‘sperare’, with the latter meaning: belief, patience and confidence.
The topical pigment corrector, distributed in the UK by AestheticSource, addresses the appearance of discolouration and dark spots. Naturally present in human skin cells, cysteamine reduces melanin in the skin.
Research on the product shows an impressive 47% melanin pigment reduction in pigmented lesions after eight weeks of use and a 67% reduction after 16 weeks. In fact, 90% of users noticed moderate to significant improvements overall.
The European Academy of Dermatology and Venerology described the highly biocompatible and tolerant product as having “a superior benefit to risk ration when compared to all other pigment correcting agents.”
The product is non-cytotoxic, non-carcinogenic and is free of hydroquinone, retinoic acid and corticosteroid.
